Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: Data on novel oral drugs

Multiple Sclerosis Journal

Volumn 17, Issue 5, 2011, Pages 630-633

  Sormani, M P ^a   Bonzano, L ^b   Roccatagliata, L ^b   De Stefano, N ^c  

^a Department of Health Sciences ^*  (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Clinical trials; Methodology study design; MRI; Multiple sclerosis; Surrogate endpoints

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ARTICLE; DISABILITY; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RELAPSE; TREATMENT OUTCOME; VALIDATION PROCESS; BRAIN; DRUG EFFECT; META ANALYSIS; ORAL DRUG ADMINISTRATION; PATHOLOGY; PREDICTIVE VALUE; RECURRENT DISEASE; REGRESSION ANALYSIS; REPRODUCIBILITY; TIME; VALIDATION STUDY;

ADMINISTRATION, ORAL; BRAIN; CLADRIBINE; DISABILITY EVALUATION; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; PROPYLENE GLYCOLS; RECURRENCE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SPHINGOSINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053399685     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458510393770     Document Type: Article

References (9)

1. Sormani MP, Filippi M, De Stefano N, Ebers G and Daumer M. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009; 73: 1932-1933.
2. Daumer M, Neuhaus A, Morrissey S, Hintzen R and Ebers GC. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009; 72: 705-711.
3. Kappos L, Radue EW, O'Connor P, et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
4. Giovannoni G, Comi G, Cook S, et al. A placebocontrolled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362: 416-426.
5. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
6. Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009; 65: 268-275.
7. Sormani MP, Bonzano L, Roccatagliata L, et al. Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach. Neurology Epub 2010 Jun 23.
8. Giovannoni G, Comi G, Cook S, et al. Clinical efficacy of cladribine tablet therapy in patients with relapsingremitting multiple sclerosis (RRMS): results from the CLARITY study, a 96-week, phase III, double-blind, placebo- controlled trial. 19th European Neurological Society Meeting. Milan, Italy, 2009.
9. Comi G, Cook S, Giovannoni G, et al. Magnetic resonance imaging (MRI) outcomes in patients with relapsing- remitting multiple sclerosis (RRMS) treated with cladribine tablets: results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial. 19th European Neurological Society Meeting. Milan, Italy, 2009.